SPIN 2019 Archives - Medical Conferences

Home > Dermatology > SPIN 2019

Skin Inflammation & Psoriasis International Network

25–27 April 2019, Paris, France

Letter from the Editor

Editor

Prof. dr Peter C.M. van de Kerkhof, Radboud University Nijmegen Medical Centre, the Netherlands

Treatment goals in psoriasis

Presented By

Prof. Ulrich Mrowietz

Aetiology: Triggers and Risk Factors

Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis

Presented By

Prof. Jonathan Barker, Kings College London, United Kingdom

Atopic dermatitis and psoriasis: on a spectrum?

Presented By

Prof. Emma Guttman-Yassky, Mount Sinai Medical School, USA

Advances in Therapy

Advances in target-oriented therapy: psoriatic arthritis

Presented By

Prof. Wolf-Henning Boehncke, University of Geneva, Switzerland

Favourable safety profile of long-term use of ixekizumab

Presented By

Prof. Kristian Reich, Georg-August-University Göttingen, Germany

Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies

Presented By

Dr Sandra Philipp, Charité-Universitätsmedizin Berlin, Germany

Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity

Presented By

Dr Gayle van der Kraaij, Amsterdam UMC, the Netherlands

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients

Presented By

Dr Sandra Phillip, Charité-Universitätsmedizin Berlin, Germany

Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis

Presented By

Prof. Peter van de Kerkhof, Radboud University Medical Center, the Netherlands

Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Novel Considerations

Granulomatous rosacea: exploratory histological markers

Presented By

Dr EunHye Hong, Hallym University Sacred Heart Hospital, Korea

Live imaging of cutaneous immune responses

Presented By

Prof. Kenji Kabashima, Kyoto University, Japan

Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?

Presented By

Prof. Kristian Reich, Georg-August-University Göttingen, Germany

ABP501 biosimilar for adalimumab: What you need to know

Presented By

Prof. Brian Kirby, St Vincent's Hospital, Dublin, Ireland

Switching infliximab biosimilars safe in treating chronic plaque psoriasis

Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies

Presented By

Prof. Lluís Puig, Hospital de la Santa Creu i Sant Pau, Spain

Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis

Presented By

Dr Nehal Mehta; Prof. Emma Guttman-Yassky

Treatment goals in psoriasis

Presented By

Prof. Ulrich Mrowietz

Small molecules, apremilast, and TYK2

Presented By

Prof. Richard Langley, Dalhousie University, Canada

Medical Conferences

SPIN 2019

Table of Contents

Featured articles

Letter from the Editor

Treatment goals in psoriasis

Aetiology: Triggers and Risk Factors

Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis

Atopic dermatitis and psoriasis: on a spectrum?

Advances in Therapy

Advances in target-oriented therapy: psoriatic arthritis

Favourable safety profile of long-term use of ixekizumab

Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies

Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients

Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis

Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease

Novel Considerations

Granulomatous rosacea: exploratory histological markers

Live imaging of cutaneous immune responses

Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?

ABP501 biosimilar for adalimumab: What you need to know

Switching infliximab biosimilars safe in treating chronic plaque psoriasis

Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies

Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis

Treatment goals in psoriasis

Small molecules, apremilast, and TYK2